The Claim
The ratio of phosphorylated tau to non-phosphorylated tau (p-tau217/np-tau217 and p-tau181/np-tau181) does not exhibit a breakpoint in population-level analyses, indicating that age-related increases in total tau protein obscure the biomarker specificity of phosphorylated tau.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In population studies, the ratio of phosphorylated tau to non-phosphorylated tau does not show a clear threshold because rising levels of total tau with age mask the distinct signal of phosphorylated tau.
See the scientific wording
The ratio of phosphorylated tau to non-phosphorylated tau (p-tau217/np-tau217 and p-tau181/np-tau181) does not show a breakpoint, suggesting that age-related increases in total tau protein mask the specificity of phosphorylated tau as a biomarker in population-level analyses.
As people age, the brain produces more of both normal and abnormal forms of tau protein, and both types spill into the blood at the same rate. Because the normal form increases just as much as the abnormal form, their ratio stays steady and doesn’t signal when the abnormal form becomes dominant.
What the research says
1 studyAs people get older, both the bad form of tau (phosphorylated) and the normal form increase together in the blood, so their ratio doesn’t suddenly change at any age — making the ratio less useful than just measuring the bad tau alone.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.